BIO Comments: Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
December 5, 2017
The Biotechnology Innovation Organization (“BIO”) welcomes the opportunity to submit written comments to supplement our previous live testimony to the FDA’s open docket on the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. BIO appreciated the opportunity to participate in FDA’s July 18th public meeting on this important topic and we are happy to supplement the record with these written comments.
BIO also supplemted the comments we filed on September 19, 2017 to better inform the Docket on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. 1 Following submission of our comments pursuant to the initial closing date, other stakeholder comments were filed that raise issues of significant concern to BIO and our members. To ensure stakeholder interests in this issue are fully and accurately reflected, BIO submits these supplemental comments for FDA’s consideration
Download Full Comments Below
Comment From Biotechnology Innovation Organization BIO (1)
Bio Comments on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
The Biotechnology Innovation Organization (“BIO”) welcomes the opportunity to submit written comments to supplement our previous live testimony to the FDA’s open docket on the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. BIO appreciated the opportunity to participate in FDA’s July 18th public meeting on this important topic and we are happy to supplement the record with these written comments.
BIO also supplemted the comments we filed on September 19, 2017 to better inform the Docket on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. 1 Following submission of our comments pursuant to the initial closing date, other stakeholder comments were filed that raise issues of significant concern to BIO and our members. To ensure stakeholder interests in this issue are fully and accurately reflected, BIO submits these supplemental comments for FDA’s consideration